Diabetes Self-Management Articles

These articles cover a wide range of subjects, from the most basic aspects of diabetes care to the nitty-gritty specifics.

Links not loading properly?

Some of our pages use Portable Document Format (PDF) files, which require Adobe Acrobat Reader. To download Acrobat Reader for free, visit www.adobe.com.

Sign up for our weekly e-mail newsletter and receive a FREE GIFT! Enter your e-mail below.

Learn more

Learn more about diabetes

Links to help you learn more about diabetes.

Ask a diabetes expert
Other diabetes resources
Browse article topics

 

Tools of the Trade 2012

by Alwa Cooper

Availability: Juvisync is available in tablets of 100 mg sitagliptin/10 mg simvastatin, 100 mg sitagliptin/20 mg simvastatin, and 100 mg sitagliptin/40 mg simvastatin.

Drug labeling changes
Product: Tapentadol extended release (Nucynta ER)

Manufacturer: Janssen
(800) JANSSEN (526-7736)
www.nucynta.com

Reason for label change: Nucynta ER (a drug in the class known as opiate analgesics) was approved in 2011 to treat moderate to severe chronic pain that necessitates constant pain management. The FDA has approved it this year specifically to treat pain from diabetic peripheral neuropathy (nerve damage in the feet, legs, and hands). Nucynta ER is taken twice daily and is available in 50-, 100-, 150-, 200-, and 250-mg tablets.


Product: Exenatide (Byetta)

Manufacturer: Amylin
(800) 868-1190
www.byetta.com

Reason for label change: The FDA has approved the use of Byetta in combination with insulin glargine (Lantus, a long-acting insulin).


Product: Insulin detemir (rDNA origin) injection (Levemir)

Manufacturer: Novo Nordisk
(800) 727-6500
www.levemir.com

Reason for label change: The FDA has approved Levemir for use by pregnant women with diabetes after the results of a clinical trial indicated that the drug did not increase the risk of harm to the fetus.


Product: Ranibizumab injection (Lucentis)

Manufacturer: Genentech USA, Inc.
(866) LUCENTIS (582-3684)
www.lucentis.com

Reason for label change: The FDA has approved Lucentis for use in treating diabetic macular edema (swelling of the central part of the retina in the eye). Lucentis had already been approved for the treatment of age-related macular degeneration.


Product: Linagliptin (Tradjenta)

Manufacturer: Boehringer Ingelheim
(800) 243-0127
www.tradjenta.com

Reason for label change: The FDA has approved Tradjenta for use in combination with insulin by people with Type 2 diabetes, and for use by people with Type 2 diabetes who also have severe, chronic kidney problems.

Page    1    2    3    4    5    6    7    8    9    Show All    

 

 

More articles on General Diabetes & Health Issues

 

 


Statements and opinions expressed on this Web site are those of the authors and not necessarily those of the publishers or advertisers. The information provided on this Web site should not be construed as medical instruction. Consult appropriate health-care professionals before taking action based on this information.

 

 

Tools of the Trade 2011
Some of the biggest changes in the diabetes market in 2011 had to do with medicines — several... Article

How can you keep an insulin pen from leaking? Get tip


Blood Glucose Self-Monitoring — Part 3: Smart Monitoring

10 Keys to Long-Term Weight Loss

Take Your Best Shot: Stay Up to Date on Vaccines

Complete table of contents
Get a FREE ISSUE
Subscription questions